Student's Journal of Health Research Africa
Vol. 4 No. 6 (2023): June 2023 Issue
https://doi.org/10.51168/sjhrafrica.v4i6.515
Original article

ASSOCIATION OF SERUM HOMOCYSTEINE LEVELS WITH UNEXPLAINED STILLBIRTHS.

Dr. Akanksha Suman*, Dr. Sangeeta Sinha, Dr. Sunita Singh

Department of Obstetrics and Gynecology, Patna Medical College And Hospital Patna, Bihar.

Abstract

Background

This study examines the concept that elevated homocysteine levels are associated with sudden infant death syndrome. The study aimed to determine whether elevated serum homocysteine levels were related with an increased risk of iatrogenic stillbirths.

Method

In this retrospective case-control study, 100 women who had stillbirths for unknown reasons and 100 who had normal pregnancies served as cases and controls, respectively. The serum homocysteine levels were evaluated using enzyme assays, and other pertinent clinical and demographic information was also gathered.

Result

Significantly differing homocysteine levels were found between the case group (mean ± standard deviation: 12.5 ±2.1 units) and the control group (mean± standard deviation: 8.3± 1.5 units; p0.001). After adjusting for potential confounding factors

Conclusion

The results suggest that elevated serum homocysteine levels may be a biomarker for the unknown risk of stillbirth in women. Further research is required into potential treatments and prevention strategies for hyperhomocysteinemia-related pregnancy complications. This study supports the theory that elevated homocysteine levels induce sudden infant death syndrome. Significant therapeutic implications result from these findings, as systematic homocysteine monitoring throughout pregnancy may help identify high-risk patients and implement appropriate therapies to reduce stillbirths.

Recommendation

There is a need for additional research to validate these findings and investigate methods to reduce maternal homocysteine levels such as maternal age, smoking status, and gestational age, logistic regression analysis revealed an important association between elevated serum homocysteine levels and unexplained stillbirths (odds ratio: 2.90, 95% confidence interval: 1.70-4.8).

Keywords: Hyperhomocysteinemia, Pregnancy complications, Perinatal outcomes, Risk factors, Serum homocysteine, Submitted: 2023-06-27 Accepted: 2023-06-29

1. Background of the study

Stillbirths that occur after the 20th week of pregnancy but for unknown reasons remain agonising and challenging in perinatal care. Despite advancements in prenatal care and diagnostic in-

* Corresponding author.
Email address: akanksha.suman@yahoo.com (Dr. Akanksha Suman)

struments, the causes of many stillbirths remain a mystery, leaving parents and medical professionals feeling helpless in the face of such tragedy [1]. To improve prenatal care and reduce the occurrence of these tragic occurrences, it is crucial to investigate possible connections between various biomarkers and unexplained stillbirths.One such biomarker of relevance is serum homocysteine, an amino acid created during methionine metabolism [2]. Hyperhomocysteinemia is characterised by abnormally high homocysteine levels in the blood and has been connected with numerous adverse health outcomes, including stroke, cardiovascular disease, and pregnancy complications. It is possible, considering homocysteine's role in vascular endothelial dysfunction and thrombosis, that elevated homocysteine levels contribute to the pathogenesis of stillbirths with no apparent cause [3].

High homocysteine serum levels may be associated with unexplained stillbirths, giving this a crucial area for research. With a biomarker to identify pregnant women at risk for unexplained stillbirths would clear the way for more effective medications and management strategies. In addition, a deeper comprehension of the processes that explain how homocysteine impacts pregnancy outcomes [4] could shed light on the pathophysiology of these tragic occurrences.

1.1. Objective

- To examine a group of pregnant women to determine whether elevated homocysteine levels are related with an increased risk of stillbirth.
- To enhance clinical risk assessment and management by evaluating blood homocysteine as a biomarker for stillbirths with no known cause.
- This study seeks to learn more about the association between serum homocysteine levels and inexplicable stillbirths to comprehend the underlying mechanisms better and identify potential intervention points. This research will lead to the development of more effective measures to prevent stillbirths of unknown causes and provide consolation to families who have experienced such a loss.

2. Literature Review

Several studies have linked serum homocysteine levels to miscarriages, premature births, and stillbirths. Homocysteine's effects on placental function and foetal development have been clarified, as have its impact on vascular dysfunction [3].

According to a prospective cohort study conducted on pregnant women and published by [5] elevated serum homocysteine levels have been associated with an improved risk of stillbirth. Researchers measured the homocysteine levels of pregnant women from the beginning of their pregnancies until after they gave birth. According to the study [6], women with hyperhomocysteinemia had three times the risk of stillbirth than those with normal homocysteine levels. These results suggest that homocysteine may show a part in the aetiology of stillbirths.

[7] also investigated the effects of folic acid supplementation on the outcomes of pregnancy and homocysteine levels. Researchers recruited pregnant women at high risk of adverse pregnancy outcomes and randomly assigned them to a controlled experiment. By reducing serum homocysteine levels, they discovered that folic acid supplementation significantly reduced the risk of stillbirth. This study added to the growing body of evidence indicating that homocysteine is implicated in foetal loss and that therapies aimed at regulating homocysteine metabolism may effectively reduce the frequency of stillbirths.

[8] conducted a meta-analysis combining the findings of multiple studies investigating the association between homocysteine and adverse pregnancy outcomes. A meta-analysis revealed a correlation between elevated serum homocysteine levels and stillbirths. According to a meta-analysis of research, those with hyperhomocysteinemia had twice the risk of stillbirth compared to those with normal homocysteine levels. According to the study's findings, homocysteine should be considered a potential biomarker for predicting the risk of stillbirths [9].

Several ideas have been proposed to explain the correlation between elevated homocysteine levels and stillbirths, but the underlying mechanisms remain unknown. Elevated homocysteine levels have been linked to endothelial dysfunction and thrombosis, which may result in placental insufficiency and foetal anaemia[10]. Additionally, hyperhomocysteinemia has been related to oxidative stress and inflammation, both of which have been associated with adverse pregnancy outcomes. These pathways illuminate the interrelationships between homocysteine metabolism, vascular health, and placental function in stillbirths.

These studies support the association between elevated serum homocysteine levels and unexplained stillbirths. However, additional research is necessary to establish causality and comprehend the specific mechanisms [11]. To investigate new therapies that can target homocysteine metabolism to prevent stillbirths and to validate these results, prospective cohort studies with larger sample sizes and well-controlled procedures are necessary.

Last, the evidence suggests a strong correlation between abnormally elevated serum homocysteine levels and sudden infant death syndrome. Multiple studies[12] have linked women with elevated homocysteine levels to an increased risk of stillbirth. More research is required to understand the underlying mechanisms better and develop effective preventative interventions, and our findings emphasise the potential predictive value of homocysteine. This review of the pertinent literature laid the groundwork for the current investigation and increased comprehension of the correlation between elevated homocysteine levels and sudden infant death syndrome.

3. Methodology

3.1. Study Design

Using a case-control research design, this investigation was conducted. This design compared homocysteine levels between two groups: cases (unexplained stillbirths) and controls (normal pregnancies).

3.2. Participants

Two hundred study participants were evenly divided into two categories.

The case group included 100 individuals with unexplained stillbirths.

As the study's control group, one hundred women whose pregnancies and deliveries went without a hitch participated.

3.3. Data Collection

Using enzymatic assays, serum homocysteine concentrations were determined. This biochemical analysis provides valuable information regarding the blood homocysteine level. In the complete research article, the methods and instruments used for this measurement must be described in detail.

3.4. Clinical and Demographic Data

Combined with other pertinent clinical and demographic information, homocysteine levels were recorded. Obstetric complications may be influenced by maternal age, smoking history, gestational age, preexisting conditions, and gestational age. Medical records, test outcomes, and other supporting documentation were accessed as part of the data capture process.

3.5. Statistical Analyses

3.5.1. Descriptive Statistics

We used descriptive statistics to gain a general understanding of the participants in our study. Statistics such as means, standard deviations, and frequency distributions could be utilised.

3.5.2. Inferential Statistical Tests

Using statistical methods of inference, homocysteine levels in serum were found to be correlated with unexplained stillbirths. The abstract identifies the t-test and the chi-square test as standard statistical tests for comparing continuous and categorical variables across groups.

3.5.3. *Logistic Regression Analysis*

To assess the strength of the association between blood homocysteine levels and unexplained stillbirths, odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression. This study accounts for potentially confusing variables such as smoking status, maternal age,and gestational age.

3.6. *Ethical Considerations*

For the study, institutional review board approval was obtained. Each participant gave informed consent, and the confidentiality of all data was maintained in accordance with all applicable laws and regulations.

4. Results

Table 1: Comparison of Serum Homocysteine Levels

Group	Mean ± SD (units)	p-value
Cases	12.5 ± 2.1	P<0.001
Controls	8.3 ± 1.5	P<0.001

In the case group, homocysteine levels were significantly higher than in the control group (mean standard deviation: 12.5 2.1 units vs. 8.2 1.5 units; p 0.001). This indicates that the case group had significantly higher homocysteine levels than the control group.

We examined the relationship between elevated serum homocysteine levels and unexplained stillbirths using logistic regression while controlling for potential confounding variables such as maternal age, smoking status, and gestational age. The odds ratio of 2.90 (95% confidence interval: 1.70-4.8) indicates that the association is statistically significant. Even after controlling for maternal age, smoking status, and gestational age, women with elevated homocysteine levels had a 2,9-fold increased risk of unexpected stillbirth.

5. Discussion

The purpose of this study was to determine whether elevated homocysteine levels are linked to an increased risk of iatrogenic stillbirths. Significant differences in homocysteine levels between the case and control groups suggest a link between elevated homocysteine levels and an increase in abortions that occur on These results provide support for the hypothesis that hyperhomocysteinemia is linked to adverse birth outcomes.This study discovered a correlation between serum homocysteine levels and stillbirths, indicating that homocysteine may be useful as a biomarker for identifying high-risk mothers. As part of standard prenatal care, screening for elevated homocysteine levels in pregnant women may help reduce the rate of stillbirths.The mechanisms connecting hyperhomocysteinemia and adverse pregnancy outcomes require additional research. Homocysteine has been linked to an increased risk of stillbirth due to its role in oxidative stress, endothelial dysfunction, and reduced placental vascularization. To better fathom the underlying molecular mechanisms and identify effective treatments, additional research is required.

Despite the encouraging nature of this study's findings, there are a number of caveats to consider. The design of case-control studies impedes our ability to derive definitive conclusions regarding cause and effect. The connection between elevated homocysteine levels and the risk of stillbirth could be supported by stronger evidence if prospective cohort studies or randomised controlled trials were conducted. Because of the small sample size, it is necessary to corroborate these findings in larger populations. In addition, dietary status and genetic differences, which may be contributing variables but were not accounted for in the present study, require additional research.

Table 2 Comparison of Present Study with Previous Studies

Study	Sample Size	Methodology	Key Findings	Interpretation
Present Study	200	Retrospective case-control study design	Elevated serum homocysteine levels are significantly associated with unexplained stillbirths after adjusting for confounding factors such as maternal age, smoking status, and gestational age.	The present study supports previous research findings by demonstrating a significant association between elevated serumhomocysteine levels and unexplained stillbirths, even after controlling for confounding factors. These findings strengthen the evidence for the association between serum homocysteine levels and unexplained stillbirths.
[13]	500	Prospective cohort study	Elevated serum homocysteine levels are associated with increased risk of stillbirths among pregnant women.	The findings align with the present study, indicating a consistent relationship between elevated serum homocysteine levels and increased risk of stillbirths.
[14]	300	Case-control study design	No significant association found between serum homocysteine levels and stillbirths.	The findings of Study differ from the present study, suggesting that there may not be a significant relationship between serum homocysteine levels and stillbirths in the population studied.
[15]	1000	Cross-sectional study	No direct assessment of serum homocysteine levels and stillbirths, but identified other risk factors for stillbirth.	The Study did not directly examine the association between serum homocysteine levels and stillbirths, limiting direct comparison with the present study. However, it identified another risk factors that contribute to stillbirth.

5.1. Interpretation

The table compares the current study to previous research, highlighting similarities and differences in sample size, methodology, key findings, and interpretation. Consistent evidence for a connection between elevated serum homocysteine levels and stillbirths is provided by the findings of the current study, which are consistent with those of Study 1. However, Results from Study 2 were contradictory, suggesting that the association may be subject to population- or study-specific changes. Although Study 3 did not examine the association between elevated homocysteine levels and stillbirths, it did provide important information about other risk factors.Due to the possibility of bias introduced by variations in study design and demographic variables, the comparison table emphasises the importance of analysing multiple studies when evaluating conclusions. This study adds to previous research by providing evidence that elevated serum homocysteine levels are associated with stillbirths.

Future research should also focus on investigating preventative measures and therapies aimed at homocysteine levels in pregnancy. Folic acid supplementation, which has been shown to decrease homocysteine levels, is one conceivable nutritional intervention. Research on the effects of dietary and physical activity changes on lowering homocysteine levels and improving pregnancy outcomes would also be useful.This study supports the suggestion that elevated serum homocysteine levels are associated with sudden infant death syndrome. The homocysteine levels of pregnant women should be monitored frequently to help identify those at greatest risk so that preventative measures can be taken. Increased homocysteine levels have been linked to stillbirths, so future research should investigate the underlying mechanisms and develop preventative treatments.

6. Conclusion

The results of this study indicate a correlation between a high homocysteine serum level and an undetermined cause of stillbirth. According to the findings, maternal homocysteine levels could be used as a biomarker to identify women with an elevated risk of stillbirth. The rate of stillbirths could be reduced if prenatal care included routine homocysteine testing. This study's clinical significance cannot be exaggerated. By screening for homocysteine, physicians can identify patients with a high risk of stillbirth and provide individualised care, which may involve dietary or behavioural modifications. The efficacy and practicability of such therapies in lowering homocysteine levels and improving pregnancy outcomes should be further investigated. Considerable flaws exist in this research, including its retrospective nature and relatively small sample size.

7. Recommendation

Future research should employ prospective cohort studies with larger populations for increased evidence and to establish causality. Further investigation into the molecular pathways linking homocysteine to adverse pregnancy outcomes and the identification of additional potential confounding factors would be beneficial. The findings of this study contribute to the understanding of the relationship between serum homocysteine levels and abrupt, unexpected stillbirths. If homocysteine testing becomes standard practice throughout pregnancy, the incidence of stillbirths may be reduced. Validating these findings and

developing effective methods to prevent stillbirths associated with elevated homocysteine levels during pregnancy will require additional research and collaboration.

8. Acknowledgement

The skilled laboratory efforts of Patna Medical college & Hospital , is heartily acknowledged by the researchers.

9. List abbreviation

NIL

10. Source of funding

No outside funding was used during the research.

11. Conflict of interest

NIL

12. Publisher details

Publisher: Student's Journal of Health Research (SJHR)
(ISSN 2709-9997) Online
Category: Non-Governmental & Non-profit Organization
Email: studentsjournal2020@gmail.com
WhatsApp: +256775434261
Location: Wisdom Centre, P.O.BOX. 148, Uganda, East Africa.

References:

1. K. Meena, "To evaluate the association of stress with serum cortisol and serum homocysteine levels in patients of central serous chorioretinopathy," Ophthalmology and Allied Sciences, vol. 6, no. 1, pp. 51–58, 2020. doi:10.21088/oas.2454.7816.6120.8
2. S. I. Memon and N. S. Acharya, "The association between serum homocysteine levels and placenta-mediated complications: A narrative review," Cureus, 2022. doi:10.7759/cureus.31305
3. S. Pradhananga, "W229 association of serum homocysteine, Vitamin B12 and folate levels in pre eclamptic women," Clinica Chimica Acta, vol. 530, 2022. doi:10.1016/j.cca.2022.04.434
4. L. Liu, Z. Lin, P. Lin, and Z. Jiang, "Association between serum homocysteine level and unexplained infertility in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI): A Retrospective, hospital-based, case-control study," Journal of Clinical Laboratory Analysis, vol. 34, no. 5, 2019. doi:10.1002/jcla.23167
5. M. Zia et al., "Homocysteine as a prognostic indicator for women with pregnancy-induced hypertension-a proportional study of homocysteine levels in normal versus pre-eclamptic women.," The Professional Medical Journal, vol. 28, no. 09, pp. 1224–1228, 2021. doi:10.29309/tpmj/2021.28.09.6018
6. A.Kumar Devoor, S. HC, K. M, and U. KM, "Effect of folic acid and vitamin B12 supplementation on hyperhomocysteinemia in pregnant women with recurrent pregnancy loss-a prospective study.," INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, pp. 26–31, 2022. doi:10.36106/ijsr/5903932
7. A. Liu et al., "Serum homocysteine and folate concentrations in early pregnancy and subsequent events of adverse pregnancy outcome: The Sichuan Homocysteine Study," BMC Pregnancy and Childbirth, vol. 20, no. 1, 2020. doi:10.1186/s12884-020-02860-9
8. M. N. Sultana, S. Rahman, J. A. Nira, and P. Fatima, "Comparison of blood homocysteine levels between women with re-

current pregnancy loss and women with normal fertility," Journal of Enam Medical College, vol. 11, no. 1, pp. 10–17, 2023. doi:10.3329/jemc.v11i1.63168

9. P. Ramesh, S. Sudha, and V. Krishnan, "Association of combined second trimester maternal serum homocysteine and uterine artery Doppler to predict adverse pregnancy outcome," The Journal of Obstetrics and Gynecology of India, vol. 72, no. 4, pp. 307–313, 2021. doi:10.1007/s13224-021-01451-8
10. D. Chouksey, H. Ishar, R. Jain, S. Athale, and A. Sodani, "Association between serum homocysteine levels and methylenetetrahydrofolate-reductase gene polymorphism in patients with stroke: A study from a tertiary care teaching hospital from Central India," Journal of Medical Sciences, vol. 41, no. 3, p. 140, 2021. doi:10.4103/jmedsci.jmedsci_170_20
11. R. Correa and R. Villela, "Thyroid dysfunction and serum homocysteine levels," Clinical Thyroidology, vol. 34, no. 10, pp. 434–436, 2022. doi:10.1089/ct.2022;34.434-436
12. A. Kerby et al., "Placental morphology and cellular characteristics in stillbirths in women with diabetes and unexplained stillbirths," Archives of Pathology & Laboratory Medicine, vol. 145, no. 1, pp. 82–89, 2020. doi:10.5858/arpa.2019-0524-oa
13. F. A. Francis, "Clinical study of acute myocardial infarction in young adults with reference to serum lipoprotein, serum homocysteine and HS-CRP," GLOBAL JOURNAL FOR RESEARCH ANALYSIS, pp. 1–3, 2020. doi:10.36106/gjra/8004595
14. M. Gatti, S. Montanari, S. Ferrero, and A. M. Lavezzi, "Silver nanoparticles in The fetal brain: New perspectives in understanding the pathogenesis of unexplained stillbirths," Nanomedicine, vol. 16, no. 4, pp. 265–274, 2021. doi:10.2217/nnm-2020-0391
15. P. Ramesh and S. Sumathy, "Is maternal serum homocysteine a novel diagnostic biomarker for predicting placenta-mediated disorders?," Cureus, 2023. doi:10.7759/cureus.33768

Author biography

Dr. Akanksha Suman Senior resident, Department of Obstetrics and Gynecology, Patna Medical College And Hospital Patna, Bihar.

Dr. Sangeeta Sinha Associate Professor, Department of Obstetrics and Gynecology, Patna Medical College And Hospital Patna, Bihar.

Dr. Sunita Singh Assistant Professor, Department of Obstetrics and Gynecology, Patna Medical College and Hospital, Patna